Influence of endostain and epithelial growth factor receptor on the survival of the perioperative no-small cell lung cancer

doi:10.3877/cma.j.issn.2095-8773.2015.02.005

Abstract

Abstract:

Objective

To investigate the influence of clinicopathological characteristics, endostain and epithelial growth factor receptor(EGFR) on the survival of the perioperative non-small cell lung cancer(NSCLC).

Methods

Fifty patients with NSCLC undergoing surgical treatment in the Department of Cardiothoracic Surgery in Shanghai Sixth People’s Hospital affiliated to Shanghai Jiao Tong University between January 2008 and December 2008 were collected, and were followed up after surgery till January 2014, with the mean time of follow-up of 36.44 months. The survival-related factors for these 50 patients with NSCLC were analyzed using multivariate regression analysis.

Results

The 5-year survival was 53.7%, and the median survival time was 50.6 months for these 50 patients with NSCLC. The survival in patients with tumor maximum dimmer <3.5 cm was significantly bigger than that in those with tumor maximum dimmer ≥3.5 cm(χ²=8.086, P=0.004). The survival in patients with adenocarcinoma was significantly bigger than that in those with squamous carcinoma(χ²=7.527, P=0.006). The survival in patients with stage Ⅰ NSCLC was significantly bigger than those in patients with stage Ⅱ and stage Ⅲ NSCLC(χ²=4.681, P =0.03; χ²=7.990, P=0.005). The survival in patients with endostatin <20.4 ng/mL before operation was significantly bigger than that in those with endostatin≥20.4 ng/mL before operation(χ²=5.213, P=0.022). The survival in patients with EGFR ≥44.7 pg/mL after operation was significantly bigger than that in those with EGFR<44.7 pg/mL after operation (χ²=13.908, P=0.000). Multivariate regression analysis indicated that EGFR after operation was an independent prognostic factor(P=0.000).

Conclusion

The patients with low level of endostain before operation and high level of EGFR after operation may gain better survival.

Key words: Non-small cell lung, cancer, Endostain, Epithelial growth factor receptor, Survival rate, Prognosis, Follow-up studies

Weiming Wu, Weiwei He, Zongli Gao, Tiancheng Zhao, Yi Yang. Influence of endostain and epithelial growth factor receptor on the survival of the perioperative no-small cell lung cancer[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2015, 02(02): 98-104.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2015.02.005

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2015/V02/I02/98

Figures/Tables 11

References 16

[1]	Naumov GN, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis：role of the microenvironment[J]. Clin Exp Metastasis, 2009，26(1)：51-60.
[2]	Zhao H, Huang Y, Xue C, et al. Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer. [J]. PLoS One, 2013，8(1): e54674
[3]	Folkman J．Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Cell Res, 2006, 312(2)：594-607.
[4]	Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models [J]. PLoS One, 2013, 8(6): e65757.
[5]	Hu MM, Hu Y, Zhang HQ, et al. Clinical significance of serum and tumor tissue endostatin evaluation in operable non-small cell lung cancer[J. Biomed Rep，2014，2(6): 898-904.
[6]	杨异，高宗礼，赵天成，等．手术对非小细胞肺癌患者血清中血管内皮生长因子受体2和内皮抑素水平的影响[J]. 肿瘤，2010，30(6)：536-538.
[7]	Tanaka T, Konno H, Baba S, et a1. Prevention of hepatic and peritoneal metastases by the angiogenesis inhibitor fr-118487 after removal of growing tumor in mice[J]. Jpn J Cancer Res, 2001，92(1)：88-94.
[8]	Kathy G, Lydia F, Sinead C, et al. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer[J]．Clin Lung Cancer，2014，15(1)：58-66.
[9]	D'Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib[J]. J Thorac Oncol，2012，7(12)：1815-1822.
[10]	Izar B, Sequist L, Lee M, et al. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers[J]．Ann Thorac Surg，2013，96(3)：962-968.
[11]	Cadranel J, Mauguen A, Faller M, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2) [J]．J Thorac Oncol, 2012，7(10)：1490-1502.
[12]	李新举，张伟，袁育康. 非小细胞肺癌血清及癌组织中EGFR蛋白定量检测[J]．第四军医大学学报，2008，29(14)：1303-1305.
[13]	Akca H, Demiray A, Yaren A, et al. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small celll lung cancer[J]. Cancer Genet，2013，206(3)：73-80.
[14]	Kim ST, Jung HY, Sung JS, et al. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? [J] Am J Clin Oncol, 2013，36(1)：57-63.
[15]	Li XF, Ren RX, Ren SX, et al. Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients[J]．Transl Oncol, 2014，7(3)：341-348.
[16]	Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer[J]．J Thorac Oncol, 2012，7(1)：115-121.

临床特征		例数	百分比(%)	χ²值	P值
性别		?	?	?	?
?	男性	32	64	1.960	0.162
?	女性	18	36	1.960	0.162
年龄		?	?	?	?
?	<64岁	24	48	0.080	0.841
?	≥64岁	26	52	0.080	0.841
吸烟指数		?	?	?	?
?	<400年支	28	56	0.360	0.549
?	≥400年支	22	44	0.360	0.549
手术方式		?	?	?	?
?	楔型切除	4	8	28.880	0.000
?	肺叶切除	42	84
?	全肺切除	4	8
肿瘤最大直径		?	?	?	?
?	<3.5 cm	24	48	0.080	0.841
?	≥3.5 cm	26	52	0.080	0.841
病理类型		?	?	?	?
?	鳞癌	14	28	0.484	0.028
?	腺癌	36	72	0.484	0.028
病理分期		?	?	?	?
?	Ⅰ期	24	48	2.480	0.289
?	Ⅱ期	14	28
?	Ⅲ期	12	24

临床特征		例数	百分比(%)	χ²值	P值
性别		?	?	?	?
?	男性	32	64	1.960	0.162
?	女性	18	36	1.960	0.162
年龄		?	?	?	?
?	<64岁	24	48	0.080	0.841
?	≥64岁	26	52	0.080	0.841
吸烟指数		?	?	?	?
?	<400年支	28	56	0.360	0.549
?	≥400年支	22	44	0.360	0.549
手术方式		?	?	?	?
?	楔型切除	4	8	28.880	0.000
?	肺叶切除	42	84
?	全肺切除	4	8
肿瘤最大直径		?	?	?	?
?	<3.5 cm	24	48	0.080	0.841
?	≥3.5 cm	26	52	0.080	0.841
病理类型		?	?	?	?
?	鳞癌	14	28	0.484	0.028
?	腺癌	36	72	0.484	0.028
病理分期		?	?	?	?
?	Ⅰ期	24	48	2.480	0.289
?	Ⅱ期	14	28
?	Ⅲ期	12	24

指标		例数	百分比(%)	χ²值	P值
术前内皮抑素		?	?	?	?
?	<20.4 ng/ml	24	48	0.080	0.841
?	≥20.4 ng/ml	26	52	0.080	0.841
术后内皮抑素		?	?	?	?
?	<12.8 ng/ml	24	48	0.080	0.841
?	≥12.8 ng/ml	26	52	0.080	0.841
术前EGFR		?	?	?	?
?	<30.5 pg/ml	24	48	0.080	0.841
?	≥30.5 pg/ml	26	52	0.080	0.841
术后EGFR		?	?	?	?
?	<44.7 pg/ml	24	48	0.080	0.841
?	≥44.7 pg/ml	26	52	0.080	0.841

指标		例数	百分比(%)	χ²值	P值
术前内皮抑素		?	?	?	?
?	<20.4 ng/ml	24	48	0.080	0.841
?	≥20.4 ng/ml	26	52	0.080	0.841
术后内皮抑素		?	?	?	?
?	<12.8 ng/ml	24	48	0.080	0.841
?	≥12.8 ng/ml	26	52	0.080	0.841
术前EGFR		?	?	?	?
?	<30.5 pg/ml	24	48	0.080	0.841
?	≥30.5 pg/ml	26	52	0.080	0.841
术后EGFR		?	?	?	?
?	<44.7 pg/ml	24	48	0.080	0.841
?	≥44.7 pg/ml	26	52	0.080	0.841

因素	χ²值	P值
性别	2.911	0.088
年龄	1.186	0.276
吸烟指数	2.627	0.105
肿瘤最大径	7.873	0.005
病理类型	7.256	0.007
病理分期	7.055	0.029
术前内皮抑素水平	5.056	0.025
术后内皮抑素水平	0.215	0.643
术前EGFR水平	0.407	0.524
术后EGFR水平	13.577	0.000 3

Please choose a citation manager

Content to export